Galapagos NV (AMS: GLPG)

Market Cap	1.73B
Revenue (ttm)	261.40M
Net Income (ttm)	282.59M
Shares Out	65.90M
EPS (ttm)	4.29
PE Ratio	55.02
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	57,249
Open	25.90
Previous Close	26.30
Day's Range	25.52 - 25.98
52-Week Range	22.00 - 39.00
Beta	0.09
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2024

About Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 683
• Stock Exchange: Euronext Amsterdam
• Ticker Symbol: GLPG

Financial Performance

In 2023, VLK's revenue was 667.35 million, an increase of 12.56% compared to the previous year's 592.87 million. Earnings were 118.45 million, an increase of 53.02%.